Philogen SpA
MIL:PHIL

Watchlist Manager
Philogen SpA Logo
Philogen SpA
MIL:PHIL
Watchlist
Price: 19.1 EUR Market Closed
Market Cap: 558.5m EUR
Have any thoughts about
Philogen SpA?
Write Note

P/S
Price to Sales

244.5
Current
21.9
Median
7.6
Industry
Higher than median
Higher than industry value

Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.

P/S
244.5
=
Market Cap
558.5m EUR
/
Revenue
2.3m EUR
All Countries
All Countries
Close
Market Cap P/S
IT
Philogen SpA
MIL:PHIL
558.5m EUR 244.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 039 618.2
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6
US
Epizyme Inc
F:EPE
94.1B EUR 1 852
AU
CSL Ltd
ASX:CSL
133.7B AUD 5.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6
US
Seagen Inc
F:SGT
39.3B EUR 17.8
NL
argenx SE
XBRU:ARGX
36.2B EUR 19.4
Revenue Growth P/S to Growth
IT
Philogen SpA
MIL:PHIL
Average P/S: 3 458 344.3
244.5
339%
0.7
FR
Pharnext SCA
OTC:PNEXF
38 039 618.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852
N/A N/A
AU
CSL Ltd
ASX:CSL
5.6
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.4
220%
0.1

P/S Forward Multiples

Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/S
3.2
2-Years Forward
P/S
26.5
3-Years Forward
P/S
5.5

See Also

Summary
PHIL intrinsic value, competitors valuation, and company profile.
DCF Valuation
PHIL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PHIL stock valuation using valuation multiples.
Wall Street Estimates
PHIL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PHIL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 210,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.